| Market Cap | 2.18M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.27M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -26.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -77.00% |
| Dividend | N/A | Price/Book | 2.50 | EPS next 5Y | - | 52W High Chg | -93.00% |
| Recommedations | - | Quick Ratio | 0.11 | Shares Outstanding | 246.93M | 52W Low Chg | 32.00% |
| Insider Own | 6.89% | ROA | -56.69% | Shares Float | 189.39M | Beta | 0.01 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.02 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 62,198 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 200 | Change | -5.42% |
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
